MAP2K1 and colorectal cancer: In addition, the resistance of colorectal cancer cells to a selective MEK1/2 inhibitor selumetinib is induced by PKA activation [129], and the resistance of colorectal cancer cells to methotrexate can be induced by cAMP signaling [130].